City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report)’s stock price reached a new 52-week low on Monday. The company traded as low as $19.19 and last traded at $21.36, with a volume of 17,035 shares traded. The stock had previously closed at $20.71.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised City Therapeutics to a “hold” rating in a research note on Saturday, October 24th.
Check Out Our Latest Report on CTY
City Therapeutics Price Performance
Insider Activity
In related news, Director Robert Nelsen acquired 170,000 shares of the firm’s stock in a transaction dated Monday, October 19th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the acquisition, the director owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Arch Venture Partners Xii, Llc bought 170,000 shares of the stock in a transaction dated Monday, October 19th. The stock was bought at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the purchase, the insider owned 13,692,507 shares in the company, valued at $246,465,126. The trade was a 1.26% increase in their position. The SEC filing for this purchase provides additional information.
City Therapeutics Company Profile
Further Reading
- Five stocks we like better than City Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
